Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.
More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
KilgourMD announced phase II clinical trial results showing 53% of menopausal women with hair loss achieved meaningful regrowth within four months, with a 60% reduction in hair shedding.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774117 |
CyanthOx™ Capsule Efficacy Study |
COMPLETED | NA |
| NCT07716748 |
For an Investigator-led Hair Study Comparing Between Healthy and Hair Loss Volunteers |
NOT_YET_RECRUITING | |
| NCT07615608 |
THERAVEX® REGENERA Tissue Care Plus for Hair Regeneration and Follicular Microenvironment Modulation |
COMPLETED | NA |
| NCT07556016 |
Evaluation of the Performance of a Nutricosmetic on Hair & Scalp in Women and Men After 3 and 6 Months |
ACTIVE_NOT_RECRUITING | NA |
| NCT07368842 |
Scalp Hair Metabolomics in Severe Obesity |
RECRUITING | |
| NCT07300813 |
Olistic_2025 for Hair Loss, Hair Growth, and Skin Improvement |
ACTIVE_NOT_RECRUITING | NA |
| NCT07271212 |
Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir |
COMPLETED | NA |
| NCT07228156 |
Study to Evaluate Xtresse Serum in Individuals With Thinning Hair |
ACTIVE_NOT_RECRUITING | NA |
| NCT07146022 |
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06985121 |
Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence |
COMPLETED | NA |
